Mahalakshmi Subramanian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mahalakshmi Subramanian has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Abduljalil M. Alsubaie
School of Systems Biology, George Mason University, Manassas, VA 20110, USA
1 shared publication - Elisa Baldelli
Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia
1 shared publication - Emanuel F. Petricoin
Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia
1 shared publication - Emna El Gazzah
Center for Applied Proteomics & Molecular Medicine, George Mason University, Manassas, VA 20110, USA
1 shared publication - Fortunato Bianconi
Independent Researcher, Belvedere 44, Montefalco, 06036 Perugia, Italy
1 shared publication - Guy B. Oldaker
Department of Mathematical Sciences George Mason University 4400 University Dr 22030 Fairfax VA
1 shared publication
Latest Publications
- Open Access
- 10 March 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (6) , 2819
Heterogeneous Off-Target Effects of Ultra-Low Dose Dimethyl Sulfoxide (DMSO) on Targetable Signaling Events in Lung Cancer In Vitro Models
Targetable alterations in cancer offer novel opportunities to the drug discovery process. However, pre-clinical testing often requires solubilization of these drugs in cosolvents like dimethyl sulfoxide (DMSO). Using a panel of cell lines commonly used for in vitro drug screening and pre-clinical testing, we explored the DMSO off-target effects on functional signaling networks, drug targets, and downstream substrates. Eight Non-Small Cell Lung Cancer (NSCLC) cell lines were incubated with three concentrations of DMSO (0.0008%, 0.002%, and 0.004% v/v) over time. Expression and activation levels of 187 proteins, of which 137 were kinases and downstream substrates, were captured using the Reverse Phase Protein Array (RPPA). The DMSO effect was heterogeneous across cell lines and varied based on concentration, exposure time, and cell line. Of the 187 proteins measured, all were statistically different in at least one comparison at the highest DMSO concentration, followed by 99.5% and 98.9% at lower concentrations. Only 46% of the proteins were found to be statistically different in more than 5 cell lines, indicating heterogeneous response across models. These cell line specific alterations modulate response to in vitro drug screening. Ultra-low DMSO concentrations have broad and heterogeneous effects on targetable signaling proteins. Off-target effects need to be carefully evaluated in pre-clinical drug screening and testing.
- 10 March 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (6) , 2819
Open AccessHeterogeneous Off-Target Effects of Ultra-Low Dose Dimethyl Sulfoxide (DMSO) on Targetable Signaling Events in Lung Cancer In Vitro Models
Targetable alterations in cancer offer novel opportunities to the drug discovery process. However, pre-clinical testing often requires solubilization of these drugs in cosolvents like dimethyl sulfoxide (DMSO). Using a panel of cell lines commonly used for in vitro drug screening and pre-clinical testing, we explored the DMSO off-target effects on functional signaling networks, drug targets, and downstream substrates. Eight Non-Small Cell Lung Cancer (NSCLC) cell lines were incubated with three concentrations of DMSO (0.0008%, 0.002%, and 0.004% v/v) over time. Expression and activation levels of 187 proteins, of which 137 were kinases and downstream substrates, were captured using the Reverse Phase Protein Array (RPPA). The DMSO effect was heterogeneous across cell lines and varied based on concentration, exposure time, and cell line. Of the 187 proteins measured, all were statistically different in at least one comparison at the highest DMSO concentration, followed by 99.5% and 98.9% at lower concentrations. Only 46% of the proteins were found to be statistically different in more than 5 cell lines, indicating heterogeneous response across models. These cell line specific alterations modulate response to in vitro drug screening. Ultra-low DMSO concentrations have broad and heterogeneous effects on targetable signaling proteins. Off-target effects need to be carefully evaluated in pre-clinical drug screening and testing.